Retinitis pigmentosa (RP) comprises a group of inherited retinal degenerations characterized

by progressive loss of photoreceptors, initially, affecting rod cells and subsequently cone cells.

This leads to night blindness, peripheral vision loss and evetually central vision impairment.

MagnoVision™ MG10 aims to support retinal function by enhancing cellular activity and

promoting neuroprotection. electromagnetic stimulation may help improve photoreceptor

resilience, support retinal metabolism and contribute to preserving visiul function.

Clinical observations have reported improvements in visual field sensitivity, contrast sensitivitity

and overall visiual function in patients undergoing adjunctive MagnoVision™ therapy.